BoomRx

BoomRx is a national pharmaceutical technology platform headquartered in Tampa, Florida, dedicated to streamlining prescription sourcing and fulfillment for healthcare providers. The company's core mission is to enhance the efficiency of pharmacy operations for medical clinics, including wellness centers, telemedicine providers, and med-spas, by reducing administrative burdens and enabling practitioners to concentrate on patient care and practice expansion.

The platform unifies access to regulated 503A and FDA-registered 503B outsourcing facility products, as well as other manufactured and brand medications, through a single, secure ordering portal. BoomRx offers a comprehensive suite of services designed to consolidate multi-pharmacy workflows, simplify state-by-state shipping complexities, and provide transparent pricing with predictable flat-rate shipping. Its portfolio includes medications for weight loss (such as oral semaglutide and tirzepatide), peptides, testosterone replacement therapy (TRT), bioidentical hormone replacement therapy (BHRT), erectile dysfunction (ED), hair loss, and dermatology, supporting diverse care models including telemedicine and hybrid practices.

Since its launch in July 2025, BoomRx has rapidly grown, surpassing $15.5 million in net order revenue and processing over 77,000 orders within its first eight months, with more than 1,750 clinics utilizing its portal nationwide. Recent developments include the introduction of a new peptide-based skincare line in April 2026, expanded access to peptide therapies in March 2026, and the launch of oral liquid formulations for Testosterone Replacement Therapy and Erectile Dysfunction in early 2026. Led by founder and president Kurt Lunkwitz, BoomRx positions itself as a fast-growing leader in pharmaceutical technology, addressing critical operational challenges in the healthcare sector.